Levels of circulating MMP-7 degraded elastin are elevated in pulmonary disorders

Area of Science:

• Pulmonary Medicine
• Biochemistry
• Biomarker Discovery

Background:

• Elastin is a key lung protein degraded by matrix metalloproteinase-7 (MMP-7).
• MMP-7's role in lung defense involves elastin degradation, but its activity is unquantified serologically in lung diseases.
• Idiopathic pulmonary fibrosis (IPF) and lung cancer are significant pulmonary disorders with unknown MMP-7 activity levels.

Purpose of the Study:

• To develop and validate an assay for quantifying MMP-7-generated elastin fragments (ELM7) in serum.
• To investigate MMP-7-derived elastin degradation in patients with IPF and lung cancer.
• To assess the potential of ELM7 as a biomarker for pathological lung tissue turnover.

Main Methods:

• Development of monoclonal antibodies against MMP-7 cleavage sites on elastin.
• Validation of an assay targeting the specific ELM7 fragment.
• Measurement of serum ELM7 levels in IPF (n=123) and lung cancer (n=40) patients compared to controls.

Main Results:

• The ELM7 assay demonstrated specificity for MMP-7 degraded elastin and the ELM7 neoepitope.
• Serum ELM7 levels were significantly elevated in IPF patients (113%, p<0.0001).
• Serum ELM7 levels were significantly elevated in lung cancer patients (96%, p<0.0001).

Conclusions:

• MMP-7-generated elastin fragments (ELM7) are quantifiable in human serum.
• ELM7 levels may serve as a biomarker reflecting pathological lung tissue turnover.
• This assay provides a novel tool for studying MMP-7 activity in pulmonary disorders.